Phase 2 N=195 Early ART to Limit Infection and Establishment of Reservoir
HIV-1 Infection
Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
Phase 3 N=33 Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
HIV
Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 1 N=16 Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
Phase 3 N=32 Effects of Intensive cART During Acute/Early HIV Infection
Acute HIV Infection
Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Early Phase 1 N=9 Autologous CD4 T-Cells in HIV (C34-CXCR4)
Hiv
Primary: The Number of Subjects With Treatment Related Adverse Events — 2; 1; 2 Participants
Phase 4 N=92 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
Phase 2 N=22 VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
HIV Infections
Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
N/A N=18 Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Acute HIV Infection
Primary: Mean White Blood Cell Count Between Treatment Groups at 2 Months — 5904; 4918 white blood cells per microliter (mcL).
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 3 N=562 Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
HIV
Primary: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure — 0.23; 0.43; 0.45 proportion of…
Phase 2 N=60 Study to Evaluate a HIV Drug for the Treatment of HIV Infection
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11 — -0.138; -0.567; -0.889; -1.279 Log10 copies per milliliter (c/mL)
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
Phase 4 N=30 An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
HIV-2 Infection
Primary: Death — 0 Participants
N/A N=114 Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
Phase 2 N=43 Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
HIV · Human Immunodeficiency Virus
Primary: Time to Virologic Failure After Initiating PRO 140 Monotherapy. — 70.71 days — p=<0.0001
N/A N=102 Suppression of HIV 1 RNA in People Living With HIV
HIV
Primary: Undetectable Viral Loads During Treatment — 70.4; 42.5 percentage of blood samples undetectable — p=<0.001
N/A N=30 HIV-related Insomnia and Inflammation
Hiv · Insomnia
Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607
Phase 1 N=21 MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
HIV-1-infection
Primary: Number of Participants With Treatment-Emerging Adverse Events — 1; 1; 4; 3 Participants
Phase 1 N=49 Study of Novel Antiretrovirals in Participants With HIV-1
HIV-1-infection
Primary: Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical…
Phase 3 N=212 HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
Infection, Human Immunodeficiency Virus I · HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks — 81; 82; 19; 18 Percentage of participants
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants